Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

[1]  Huiping Li,et al.  Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer , 2021, Breast Cancer Research and Treatment.

[2]  A. Efeyan,et al.  The mTOR–Autophagy Axis and the Control of Metabolism , 2021, Frontiers in Cell and Developmental Biology.

[3]  J. Xia,et al.  MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights , 2021, Nucleic Acids Res..

[4]  P. Neven,et al.  The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer , 2021, Breast Cancer Research and Treatment.

[5]  I. Ellis,et al.  The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer , 2021, Nature Medicine.

[6]  Jason Gertz,et al.  A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-Negative Breast Cancer Anoikis Resistance. , 2020, Endocrinology.

[7]  A. Sapino,et al.  AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors , 2020, Cells.

[8]  A. G. García Carrancá,et al.  mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer , 2019, Front. Oncol..

[9]  D. Seals,et al.  The plasma metabolome as a predictor of biological aging in humans , 2019, GeroScience.

[10]  W. Wu,et al.  Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer. , 2019, Pharmacological research.

[11]  Y. Niu,et al.  A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer , 2019, Cancer Chemotherapy and Pharmacology.

[12]  M. McIlroy,et al.  The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology , 2018, Front. Endocrinol..

[13]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[14]  V. Tjan-Heijnen,et al.  Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer , 2018, Current Treatment Options in Oncology.

[15]  B. Bjørndal,et al.  Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice , 2018, Nutrition & Metabolism.

[16]  J. Bergh,et al.  RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. , 2018, Journal of the National Cancer Institute.

[17]  A. D’Alessandro,et al.  A three-minute method for high-throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathways. , 2017, Rapid communications in mass spectrometry : RCM.

[18]  Kyunghee Park,et al.  Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes , 2017, Oncotarget.

[19]  Gordon B Mills,et al.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors , 2014, Breast Cancer Research.

[20]  R. Chen,et al.  The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation , 2014, The Journal of cell biology.

[21]  C. Palmieri,et al.  Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer , 2014, The British journal of surgery.

[22]  R. Yelensky,et al.  Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms , 2014, Oncotarget.

[23]  Emanuel F Petricoin,et al.  Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.

[24]  A. Thor,et al.  Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide , 2014, Breast Cancer Research.

[25]  K. Helzlsouer,et al.  Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy , 2011, Breast Cancer Research and Treatment.

[26]  Gary Hattersley,et al.  Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. , 2011, ACS medicinal chemistry letters.

[27]  R. Tamimi,et al.  Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.

[28]  S. Hilsenbeck,et al.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[29]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[30]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[31]  R. Pommier,et al.  High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. , 2001, Surgery.